Sino Biopharmaceutical Limited (1177.HK) is in Healthcare, Biotechnology, based in Hong Kong, listed on HKSE. Market cap 96.35B HKD. 52-week range 4.19 to 8.08 HKD. Trailing P/E 36.1. Data as of 2026-10-09.
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection ...